GLP1R and type 2 diabetes mellitus: However, the treatment landscape of CKD and T2D is evolving rapidly with the introduction of new agents such as sodium–glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and finerenone.